SCHEMBL31687136

SCHEMBL31687136

COc1cc(/C=C\c2ccc3c(c2)c(C#N)cn3C)cc(OC)c1OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 11/20 0.48
TUBB4A P04350 7/20 0.48
TUBB P07437 7/20 0.48
TUBA3C P0DPH7 7/20 0.48
TUBA1B P68363 7/20 0.48
TUBA4A P68366 7/20 0.48
TUBB4B P68371 7/20 0.48
TUBB3 Q13509 7/20 0.48
TUBB2A Q13885 7/20 0.48
TUBB8 Q3ZCM7 7/20 0.48
TUBA3E Q6PEY2 7/20 0.48
TUBA1A Q71U36 7/20 0.48
TUBA1C Q9BQE3 7/20 0.48
TUBB6 Q9BUF5 7/20 0.48
TUBB2B Q9BVA1 7/20 0.48
SLC22A2 O15244 1/20 0.46
SLCO2B1 O94956 1/20 0.46
ABCB1 P08183 1/20 0.46
SLC22A6 Q4U2R8 1/20 0.46
SLC22A8 Q8TCC7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31687153 0.86 CYP1A1 (0.54) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL6088237 0.79 SRC (0.47) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31687079 0.79 TUBB1 (0.52) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31687084 0.78 TUBB1 (0.50) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31687160 0.77 TUBB1 (0.53) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31687125 0.76 TUBB1 (0.47) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31687180 0.76 TUBB1 (0.52) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31687121 0.76 HDAC8 (0.58) TUBB1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL31687177 0.75 IMPDH2 (0.54)
SCHEMBL24182135 0.74 IMPDH2 (0.54) SRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4620466-A1 TRIMETHOXYSTYRYL DERIVATIVES FOR USE IN THE TREATMENT OF PACLITAXEL-RESISTANT CANCER Instituto de Investigación Biomédica de Salamanca De la Fundación Instituto Ciencia de la Salud De Castilla y León (ES) 2025-09-24 EP disclosed